Popular
DFTX · Medicine & biotech · U.S.

Definium Therapeutics

Formerly MindMed, it develops an LSD-based pill for anxiety.

Company Health

Its yearly reports don’t have enough numbers to give it a score.
Its yearly figures are still below.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Definium Therapeutics’ yearly reports. Tap a year to see its figures.

Sales and profit

It lost money every year.
2025
Loss
$184 million

What it owns and what it owes

At the end of 2025 it owned $440 million, including $258 million in cash, and owed $108 million.

Key facts

From its yearly report for 2025.
Loss
$184 million
Cash in the bank
$258 million
Everything it owes
$108 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 26, 2026
Figures from Definium Therapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy